Therapeutic advances in COVID-19

[1]  G. Pantaleo,et al.  Antibodies to combat viral infections: development strategies and progress , 2022, Nature Reviews Drug Discovery.

[2]  G. Guyatt,et al.  Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. , 2022, The New England journal of medicine.

[3]  L. Riella,et al.  Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave , 2022, American Journal of Transplantation.

[4]  M. Meade,et al.  Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial. , 2022, JAMA.

[5]  Q. Bassat,et al.  Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients , 2022, Nature Communications.

[6]  D. Brodie,et al.  Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study , 2022, BMJ.

[7]  V. Lemée,et al.  Efficacy of anti–SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients , 2022, Kidney International.

[8]  M. T. Medina,et al.  Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses , 2022, The Lancet.

[9]  M. Pangalos,et al.  Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 , 2022, The New England journal of medicine.

[10]  F. Harrell,et al.  Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19 , 2022, JAMA internal medicine.

[11]  G. Guyatt,et al.  Effect of Early Treatment with Ivermectin among Patients with Covid-19 , 2022, The New England journal of medicine.

[12]  A. Casadevall,et al.  Early Outpatient Treatment for Covid-19 with Convalescent Plasma , 2022, The New England journal of medicine.

[13]  Christopher M. Horvat,et al.  Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2022, JAMA.

[14]  D. Segev,et al.  Quantifying excess deaths among solid organ transplant recipients in the COVID‐19 era , 2022, American Journal of Transplantation.

[15]  A. Cathcart,et al.  Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2022, JAMA.

[16]  D. Salerno,et al.  Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID‐19 in solid organ transplant recipients , 2022, American Journal of Transplantation.

[17]  K. C. Morris,et al.  Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis , 2022, medRxiv.

[18]  N. Kamar,et al.  Early Administration of Anti–SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients , 2022, Kidney International Reports.

[19]  T. Rice,et al.  Association Between Availability of ECMO and Mortality in COVID-19 Patients Eligible for ECMO: A Natural Experiment. , 2022, American journal of respiratory and critical care medicine.

[20]  S. Kaname,et al.  Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2 , 2022, Clinical and Experimental Nephrology.

[21]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[22]  R. Schinazi,et al.  Lethal mutagenesis as an antiviral strategy , 2022, Science.

[23]  Q. Bassat,et al.  High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial , 2022, The Lancet Respiratory Medicine.

[24]  S. de Bono,et al.  Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial , 2022, The Lancet Respiratory Medicine.

[25]  Shinji Watanabe,et al.  Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant , 2022, The New England journal of medicine.

[26]  Bethany S. Jones,et al.  Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. , 2022, JAMA.

[27]  M. Sise,et al.  A Propensity Score–Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease , 2021, Kidney360.

[28]  R. Lopes,et al.  Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[29]  M. Landray,et al.  Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[30]  M. Landray,et al.  Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[31]  J. Skarbinski,et al.  Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.

[32]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[33]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[34]  T. Hirai,et al.  Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction , 2021, CPT: pharmacometrics & systems pharmacology.

[35]  Marcelo A. Falappa,et al.  Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial , 2021, BMJ.

[36]  P. Ridker,et al.  Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. , 2021, JAMA.

[37]  J. Halperin,et al.  Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.

[38]  Peter J. Richardson,et al.  Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[39]  John D. Davis,et al.  REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 , 2021, The New England journal of medicine.

[40]  H. Tedesco-Silva,et al.  Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis , 2021, Transplantation.

[41]  Kelly A. Fusco,et al.  Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial , 2021, Nature Medicine.

[42]  Kunihiko Takahashi,et al.  Effect of IV High-Dose Vitamin C on Mortality in Patients With Sepsis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials* , 2021, Critical care medicine.

[43]  Brenda J. Crowe,et al.  Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial , 2021, The Lancet Respiratory Medicine.

[44]  D. Beiser,et al.  Early Convalescent Plasma for High-Risk Outpatients with Covid-19 , 2021, The New England journal of medicine.

[45]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[46]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[47]  J. Laffey,et al.  Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial , 2021, The Lancet Respiratory Medicine.

[48]  K. Gajiwala,et al.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.

[49]  D. Skovronsky,et al.  Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.

[50]  Matthew A. Wiles,et al.  Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial , 2021, Intensive Care Medicine.

[51]  Victor G. Puelles,et al.  Convalescent plasma treatment for early post‐kidney transplant acquired COVID‐19 , 2021, Transplant infectious disease : an official journal of the Transplantation Society.

[52]  Peter J. Godolphin,et al.  Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. , 2021, JAMA.

[53]  L. Forni,et al.  Pathophysiology of COVID-19-associated acute kidney injury , 2021, Nature Reviews Nephrology.

[54]  F. Pelorosso,et al.  Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial , 2021, EClinicalMedicine.

[55]  J. Koopmeiners,et al.  A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19 , 2021, EClinicalMedicine.

[56]  E. Robilotti,et al.  Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 , 2021, JAMA oncology.

[57]  Á. Avezum,et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[58]  C. Wade,et al.  Acquired antithrombin deficiency is a risk factor for venous thromboembolism after major trauma. , 2021, Thrombosis research.

[59]  Steve B Jones,et al.  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, Lancet.

[60]  M. Plattén,et al.  COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system , 2021, Nature Communications.

[61]  P. Taylor,et al.  Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.

[62]  K. Davidson,et al.  Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry , 2021, Blood.

[63]  S. Bornstein,et al.  Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19 , 2021, The Lancet Microbe.

[64]  A. Kotanidou,et al.  Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies , 2021, Critical Care.

[65]  H. Al‐Samkari.  Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19. , 2021, JAMA.

[66]  M. Landray,et al.  Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[67]  A. Clark,et al.  Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19 , 2021, JAMA network open.

[68]  S. Goodman,et al.  Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. , 2021, JAMA.

[69]  Christopher M. Horvat,et al.  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.

[70]  Samantha K. Brenner,et al.  Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019–Related Respiratory Failure* , 2021, Critical care medicine.

[71]  B. Gualano,et al.  Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[72]  D. Leaf,et al.  Vitamin D3 to Treat COVID-19: Different Disease, Same Answer. , 2021, JAMA.

[73]  Samantha K. Brenner,et al.  d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019 , 2021, Critical care medicine.

[74]  H. Schünemann,et al.  American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 , 2021, Blood Advances.

[75]  M. Desai,et al.  Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection , 2021, JAMA network open.

[76]  Jason Y. Adams,et al.  Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19 , 2021, Intensive Care Medicine.

[77]  Jason Y. Adams,et al.  Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19 , 2021, Annals of Internal Medicine.

[78]  C. Granger,et al.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[79]  P. Brennan,et al.  Characteristics, Outcomes, and Trends of Patients With COVID-19–Related Critical Illness at a Learning Health System in the United States , 2021, Annals of Internal Medicine.

[80]  F. Polack,et al.  Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.

[81]  Rhea Bhargava,et al.  Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. , 2020, Kidney360.

[82]  Z. Meng,et al.  Pilot trial of high-dose vitamin C in critically ill COVID-19 patients , 2020, Annals of Intensive Care.

[83]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[84]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[85]  D. Leaf,et al.  Tocilizumab in Covid-19. , 2020, The New England journal of medicine.

[86]  Samuel M. Brown,et al.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 , 2020, The New England Journal of Medicine.

[87]  R. Sherer,et al.  Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  Cameron R. Wolfe,et al.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.

[89]  R. Bhattacharyya,et al.  Remdesivir in Patients With Estimated GFR <30 ml/min per 1.73 m2 or on Renal Replacement Therapy , 2020, Kidney International Reports.

[90]  E. Neumann-Haefelin,et al.  Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study , 2020, BMC Nephrology.

[91]  H. Al‐Samkari,et al.  Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19 , 2020, Blood.

[92]  Eric A. Meyerowitz,et al.  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.

[93]  M. Massari,et al.  Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[94]  Samantha K. Brenner,et al.  Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. , 2020, JAMA internal medicine.

[95]  Samantha K. Brenner,et al.  AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[96]  S. Patil,et al.  Safety of Remdesivir in Patients with Acute or Chronic Kidney Disease , 2020, Kidney International Reports.

[97]  P. Czarnecki,et al.  Filter clotting with continuous renal replacement therapy in COVID-19 , 2020, Journal of Thrombosis and Thrombolysis.

[98]  Jason Y. Adams,et al.  Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States , 2020, American Journal of Kidney Diseases.

[99]  Sean M. O'Brien,et al.  Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials , 2020, medRxiv.

[100]  J. Connors,et al.  The coagulopathy, endotheliopathy, and vasculitis of COVID-19 , 2020, Inflammation Research.

[101]  M. Seshadri,et al.  Intervention in COVID-19 linked hypercoaguable states characterized by circuit thrombosis utilizing a direct thrombin inhibitor , 2020, Thrombosis Update.

[102]  Benjamin S. Glicksberg,et al.  AKI in Hospitalized Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[103]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[104]  Javier A. Neyra,et al.  Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States , 2020, American Journal of Transplantation.

[105]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[106]  Christopher J. Hogan,et al.  Aerosol Generation from the Respiratory Tract with Various Modes of Oxygen Delivery , 2020, American journal of respiratory and critical care medicine.

[107]  H. Al‐Samkari,et al.  Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID‐19) , 2020, American journal of hematology.

[108]  S. Normand.  The RECOVERY Platform , 2020, The New England journal of medicine.

[109]  Anand Srivastava,et al.  Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. , 2020, JAMA internal medicine.

[110]  C. D. Dela Cruz,et al.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.

[111]  S. Pittaluga,et al.  Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series , 2020, EClinicalMedicine.

[112]  M. Massari,et al.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[113]  G. Raskob,et al.  Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients , 2020, Journal of the American College of Cardiology.

[114]  A. Sfera,et al.  Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis , 2020, Frontiers in immunology.

[115]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[116]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[117]  H. Maecker,et al.  Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis , 2020, medRxiv.

[118]  Sheng-Chia Chung,et al.  Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom , 2020, The New England journal of medicine.

[119]  Xiao-Neng Mo,et al.  Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study , 2020, American journal of respiratory and critical care medicine.

[120]  J. Marini,et al.  Management of COVID-19 Respiratory Distress. , 2020, JAMA.

[121]  Xiaotao Lu,et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice , 2020, Science Translational Medicine.

[122]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[123]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[124]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target , 2020, Intensive Care Medicine.

[125]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[126]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[127]  Recovery Collaborative Group.  Lopinavir-Ritonavir in Hospitalised Patients with COVID-19: Preliminary Report from a Randomised, Controlled, Open-Label, Platform Trial , 2020, SSRN Electronic Journal.

[128]  R. Hyzy,et al.  Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients. , 2019, The New England journal of medicine.

[129]  David T. Huang,et al.  Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. , 2019, The New England journal of medicine.

[130]  Hyunsoon Cho,et al.  Effect of Antihypertensive Medications on Sepsis-Related Outcomes: A Population-Based Cohort Study* , 2019, Critical Care Medicine.

[131]  S. Faubel,et al.  Pulmonary Consequences of Acute Kidney Injury. , 2019, Seminars in nephrology.

[132]  Arthur S Slutsky,et al.  Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial , 2018, JAMA.

[133]  D. Leaf,et al.  De novo NAD+ biosynthetic impairment in acute kidney injury in humans , 2018, Nature Medicine.

[134]  S. Cammarata,et al.  Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment , 2018, Journal of clinical pharmacology.

[135]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[136]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[137]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[138]  M. Bhasin,et al.  PGC1α-dependent NAD biosynthesis links oxidative metabolism to renal protection , 2016, Nature.

[139]  Cheng-Li Lin,et al.  A population-based cohort study. , 2015 .

[140]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[141]  A. Berghold,et al.  Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. , 2014, JAMA.

[142]  Yves Cohen,et al.  Acute respiratory distress syndrome and risk of AKI among critically ill patients. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[143]  C. Zhang,et al.  Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets , 2014, Nature Reviews Cardiology.

[144]  E. Akl,et al.  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[145]  S. Jaber,et al.  Prone positioning in severe acute respiratory distress syndrome. , 2013, The New England journal of medicine.

[146]  D. Caldeira,et al.  Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[147]  T. Baglin,et al.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[148]  Gavin Giovannoni,et al.  A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. , 2010, Genome research.

[149]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[150]  I. Harris,et al.  A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2010 .

[151]  F. Schmidt.  Meta-Analysis , 2008 .

[152]  A. Folsom,et al.  Chronic kidney disease increases risk for venous thromboembolism. , 2008, Journal of the American Society of Nephrology : JASN.

[153]  P. Nicoletti,et al.  Novel therapeutic targets , 2006, Neurological Sciences.

[154]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[155]  P. Wells,et al.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.

[156]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[157]  Y. Yamaguchi,et al.  Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver , 1996, Digestive Diseases and Sciences.

[158]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[159]  S. Hampson.  Randomised, placebo-controlled trial , 2002 .

[160]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[161]  J. Warren,et al.  The natural experiment. , 1970, Medical times.

[162]  W Penfield,et al.  University Medicine. , 1962, Canadian Medical Association journal.